Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

High-risk myeloma remains a perplexing disease due to poor outcomes and the lack of high-risk specific guidelines. Most of  the multiple myeloma clinical trials are designed for all comers. The percentage of patients with high-risk disease in most myeloma clinical trials is small, making it hard to draw any impactful conclusions. ACCRU Study MY-1901, conducted by primary investigator Dr. Shebli Atrash and his team, is designed specifically to evaluate the outcomes of patients with high-risk disease. For more information on the study, go here: